Table I.

Clinicopathological data of patients with hepatocellular carcinoma.

		FXYD3 protein expression
Variables	Cases, n	Low, n (%)	High, n (%)	P-valuea
Age, years
≤50	70	43 (61.4)	27 (38.6)	0.231
>50	67	34 (50.7)	33 (49.3)
Sex
Male	124	69 (55.6)	55 (44.4)	0.775
Female	13	8 (61.5)	5 (38.5)
Hepatitis B surface antigen
Negative	69	39 (56.5)	30 (43.5)	0.604
Positive	68	38 (55.9)	30 (44.1)
Serum AFP, µg/ml
≤400	86	47 (54.7)	39 (45.3)	0.722
>400	51	30 (58.8)	21 (41.2)
Tumor size, cm
≤5	60	37 (61.7)	23 (38.3)	0.299
>5	77	40 (51.9)	37 (48.1)
Tumor no.
Single	100	63 (63.0)	37 (37.0)	0.011b
Multiple	37	14 (37.8)	23 (62.2)
Microvascular invasion
No	123	66 (53.7)	57 (46.3)	0.092
Yes	14	11 (78.6)	3 (21.4)
Liver cirrhosis
No	90	48 (53.9)	41 (46.1)	0.591
Yes	47	28 (59.6)	19 (40.4)
Differentiation grade
I+II	74	41 (55.4)	33 (44.6)	0.864
III+IV	63	36 (57.1)	27 (42.9)
TNM stage
I	88	55 (62.5)	33 (37.5)	0.051
II+III+IV	49	22 (44.9)	27 (55.1)

AFP, α fetoprotein; TNM, tumor-node-metastasis; FYXD3, FXYD domain-containing ion transport regulator 3.

^aχ² test.

^bP<0.05.